Kezar Life Sciences gets 180-day extension to regain Nasdaq minimum bid; transfers to Capital Market

Kezar Life Sciences, Inc.

Received Nasdaq notice on May 31, 2024 approving transfer to Nasdaq Capital Market and additional 180-day compliance period until Nov 25, 2024.
Common stock had not regained compliance with $1.00 minimum bid price since initial notice in December 2023.
Transfer to Nasdaq Capital Market effective June 4, 2024; ticker remains KZR.
Company will monitor bid price and may consider a reverse stock split to meet the requirement.
Failure to comply by Nov 25, 2024 could result in delisting; appeal rights exist but no assurance of success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.